You seem agree with my point that the “negotiation” by the government of bulk purchases “allows them to set the price”. Vaccines were an example of that. That problem would be exacerbated if applied to other drugs which require R&D, clinical trials, approval, and which afford no liability protection, require marketing etc. A company which created new drugs at low profitability for the public good would not last long. Notice that there are no new drugs being developed and marketed at low probability even by socialists, liberals, communists, or saints like Mother Theresa. Even the vaccines are mostly produce by companies making profits from other drugs. It is just not possible. It is only another pipe dream of what someone ELSE should do.
As I indicated in my previous post, the government does set the price but that's not the full picture of what is happening in a unique sector of the pharmaceutical market (which accounts for 3% of sales).
The reason that both sides (governments and pharmaceutical manufacturers) agreed to contract pricing is that the governments buy
millions of doses of these vaccines- whether they actually use them or not. In the case of flu vaccines, these are used. In the case of other unique vaccines, these are largely stockpiled by the government. In exchange for this, vaccine manufacturers have a unique exemption from legal liability for any harm that may result to patients who receive the vaccine.
Once upon a time, thousands of children died or were incapacitated by diseases that most Americans will never see. Thanks to this unique partnership between government and pharmaceutical companies, diseases like polio and pertussis are very rare and smallpox has been eradicated.
You're trying to make an analogy between vaccines that prevent disease and drugs that, for the most part, manage symptoms. You're also comparing bulk purchasing of vaccines to per-prescription purchases of medications. Neither of these is a valid comparison.
We have already seen the effects of government pricing on pharmaceuticals- the VA system negotiates bulk pricing. The VA system has 174,000 patients with hepatitis C. Harvoni, a drug used to treat hepatitis C, was costing the VA $68,000 per patient to administer. When the VA discovered that the drug only cost Gilead $1,400 to manufacture (a $66,600 profit), they negotiated the price down to where the cost per patient was lowered to between $25,000 to $37,500. In exchange, Congress allocated addition funding for the VA program and now the VA pays $696 million, or 17 percent of its total pharmacy budget to buy Harvoni.
So, in this example, the VA was able to reduce cost by 60%, Gilead still makes a profit of $35,600 per patient and Gilead gained another 174,000 patients (netting Gilead $6,194,400,000 in profit).